Riamilovir sodium hydrate | 928659-17-0 | Antiviral

Riamilovir sodium hydrate
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330050

CAS#: 928659-17-0 (sodium hydrate)

Description: Riamilovir, also known as Triazavirin, is an antiviral. Riamilovir has antiviral activity against influenza strains (such as H5N1), tick-borne encephalitis virus, and forest-spring encephalitis virus. It is being investigated for activity against Lassa fever, Ebola virus disease, and SARS-CoV-2.

Chemical Structure

Riamilovir sodium hydrate

CAS# 928659-17-0 (sodium hydrate)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 330050
Name: Riamilovir sodium hydrate
CAS#: 928659-17-0 (sodium hydrate)
Chemical Formula: C5H7N6NaO5S
Exact Mass: 286.01
Molecular Weight: 286.200
Elemental Analysis: C, 20.98; H, 2.47; N, 29.37; Na, 8.03; O, 27.95; S, 11.20

Price and Availability

Size	Price	Availability
50mg	USD 450	2 Weeks
100mg	USD 750	2 Weeks
200mg	USD 1250	2 Weeks
500mg	USD 2650	2 Weeks
1g	USD 3650	2 Weeks
2g	USD 6250	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 116061-59-7 (sodium) 123606-06-4 (free) 928659-17-0 (sodium hydrate),

Synonym: Riamilovir sodium hydrate; Riamilovir; Triazavirin; TZV;

IUPAC/Chemical Name: sodium;7-methylsulfanyl-3-nitro-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-olate;dihydrate

InChi Key: GDVSBVWTWGUDAW-UHFFFAOYSA-M

InChi Code: InChI=1S/C5H4N6O3S.Na.2H2O/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5;;;/h12H,1H3;;2*1H2/q;+1;;/p-1

SMILES Code: CSC1=NN2C(=C(N=NC2=N1)[N+](=O)[O-])[O-].O.O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	In vivo, riamilovir (1 mg/kg) inhibits lung viral accumulation in a mouse model of H5N1 influenza A infection. riamilovir (20 mg/kg) inhibits platelet aggregation in a rat model of LPS-induced hypercytokinemia. Formulations containing riamilovir have been used in the treatment of influenza.
In vitro activity:	A concentration of 128 mcg/ml of riamilovir inhibited tick-borne encephalitis virus reproduction in the SKEV cell culture. Reference: Antibiot Khimioter. 2014;59(1-2):3-5. https://pubmed.ncbi.nlm.nih.gov/25051708/
In vivo activity:	During the observation period of this study, riamilovir inhibited influenza virus A accumulation in the lungs of the infected albino mice infected with influenza virus A by more than 3 lg. Reference: Antibiot Khimioter. 2011;56(1-2):10-2. https://pubmed.ncbi.nlm.nih.gov/21780665/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	3.0	10.48
	DMSO	5.0	17.47

Preparing Stock Solutions

The following data is based on the product molecular weight 286.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. [Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]. Antibiot Khimioter. 2014;59(1-2):3-5. Russian. PMID: 25051708. 2. Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN. [Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]. Antibiot Khimioter. 2007;52(11-12):18-20. Russian. PMID: 19275052. 3. Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)]. Antibiot Khimioter. 2011;56(1-2):10-2. Russian. PMID: 21780665. 4. Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Triazavirin prophylactic efficacy against influenza virus A (H5N1)]. Antibiot Khimioter. 2010;55(9-10):25-8. Russian. PMID: 21400750.
In vitro protocol:	1. Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. [Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]. Antibiot Khimioter. 2014;59(1-2):3-5. Russian. PMID: 25051708. 2. Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN. [Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]. Antibiot Khimioter. 2007;52(11-12):18-20. Russian. PMID: 19275052.
In vivo protocol:	1. Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)]. Antibiot Khimioter. 2011;56(1-2):10-2. Russian. PMID: 21780665. 2. Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Triazavirin prophylactic efficacy against influenza virus A (H5N1)]. Antibiot Khimioter. 2010;55(9-10):25-8. Russian. PMID: 21400750.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, Li Y, Cai B, Zhu L, Zhang M, Hu X, Gao J, Wang Y, Qin H, Wang W, Zhao M, Wu X, Zhang Y, Li L, Li K, Du Z, Mol BWJ, Yang B. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. Engineering (Beijing). 2020 Sep 8. doi: 10.1016/j.eng.2020.08.011. Epub ahead of print. PMID: 32923016; PMCID: PMC7476906.

2: Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, Li Y, Cai B, Zhu L, Zhang M, Hu X, Gao J, Wang Y, Qin H, Zhao M, Zhang Y, Li K, Du Z, Yang B. The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol. Engineering (Beijing). 2020 Jul 3. doi: 10.1016/j.eng.2020.06.011. Epub ahead of print. PMID: 32837750; PMCID: PMC7332434.

3: Shahab S, Sheikhi M. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study. Curr Mol Med. 2020 May 20. doi: 10.2174/1566524020666200521075848. Epub ahead of print. PMID: 32436829.

4: Zabrodskaya YA, Shvetsov AV, Tsvetkov VB, Egorov VV. A double-edged sword: supramolecular complexes of triazavirine display multicenter binding effects which influence aggregate formation. J Biomol Struct Dyn. 2019 Aug;37(12):3041-3047. doi: 10.1080/07391102.2018.1507837. Epub 2018 Nov 15. PMID: 30073907.

5: Shvetsov AV, Zabrodskaya YA, Nekrasov PA, Egorov VV. Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure. J Biomol Struct Dyn. 2018 Aug;36(10):2694-2698. doi: 10.1080/07391102.2017.1367329. Epub 2017 Sep 12. PMID: 28828928.

6: Kozhikhova KV, Ivantsova MN, Tokareva MI, Shulepov ID, Tretiyakov AV, Shaidarov LV, Rusinov VL, Mironov MA. Preparation of chitosan-coated liposomes as a novel carrier system for the antiviral drug Triazavirin. Pharm Dev Technol. 2018 Apr;23(4):334-342. doi: 10.1080/10837450.2016.1242624. Epub 2016 Oct 25. PMID: 27681534.

7: Loginova SY, Borisevich SV, Rusinov VL, Ulomsky EN, Charushin VN, Chupakhin ON, Sorokin PV. [Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice]. Antibiot Khimioter. 2015;60(7-8):11-3. Russian. PMID: 26863736.

8: Loginova SY, Borisevich SV, Rusinov VL, Ulomsky UN, Charushin VN, Chupakhin N, Sorokin PV. [Investigation of Prophylactic Efficacy of Triazavirin Against Experimental Forest- Spring Encephalitis on Albino Mice]. Antibiot Khimioter. 2015;60(5-6):8-11. Russian. PMID: 26852489.

9: Blazhennikova IV, Kurliakova AF, Bykov VN, Geĭbo DS, Nikiforov AS, Stepanov AV, Charushin VN, Chupakhin ON, Kotovskaia SK, Rusinov VL. [Experimental comparative pharmacokinetics of levofloxacin, triazavirin, and related conjugate]. Eksp Klin Farmakol. 2015;78(2):34-8. Russian. PMID: 25898546.

10: Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. [Investigation of Triazavirin antiviral activity against tick- borne encephalitis pathogen in cell culture]. Antibiot Khimioter. 2014;59(1-2):3-5. Russian. PMID: 25051708.

11: Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, Charushin VN, Chupakhin ON. [A new antiviral drug Triazavirin: results of phase II clinical trial]. Vopr Virusol. 2012 Nov-Dec;57(6):9-12. Russian. PMID: 23477247.

12: Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. [Toxicity of triazavirin, a novel Russian antiinfluenza chemotherapeutic]. Antibiot Khimioter. 2012;57(11-12):8-10. Russian. PMID: 23700930.

13: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)]. Antibiot Khimioter. 2011;56(1-2):10-2. Russian. PMID: 21780665.

14: Smirnova TD, Danilenko DM, Eropkin MIu, Deeva EG, Kiselev OI. [Influence of rimantadine, ribavirine and triazavirine on influenza A virus replication in human monolayer and lymphoblastoid cell lines]. Antibiot Khimioter. 2011;56(11-12):11-6. Russian. PMID: 22856151.

15: Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, Deeva E, Yanvarev D, Ivanov A, Smirnova O, Kochetkov S, Chupakhin O, Kukhanova M. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrob Agents Chemother. 2010 May;54(5):2017-22. doi: 10.1128/AAC.01186-09. Epub 2010 Mar 1. PMID: 20194696; PMCID: PMC2863629.

16: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Triazavirin prophylactic efficacy against influenza virus A (H5N1)]. Antibiot Khimioter. 2010;55(9-10):25-8. Russian. PMID: 21400750.

17: Lukovnikova LV, Sidorin GI, D'iakova LI, Skhodkina NI, Bitti MA, Cherkashchenko OS. [Basing approximate safe level of exposure to Triazavirin in air of workplace]. Med Tr Prom Ekol. 2009;(4):44-7. Russian. PMID: 19514171.

18: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN. [Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]. Antibiot Khimioter. 2007;52(11-12):18-20. Russian. PMID: 19275052.

Your view history

Riamilovir sodium hydrate new featured